A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies.

Trial Profile

A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Mar 2017 Status changed from active, no longer recruiting to completed according to results published in the Targeted Oncology.
    • 29 Mar 2017 Results published in the Targeted Oncology
    • 17 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top